Cyclodextrin-based anti-microbial therapy
Cyclodextrin-based antimicrobial/antiviral therapy discovered at the University of Southern California
A rapidly deployable nanoscale biodegradable system using hydroxypropyl beta cyclodextrin-based combination product is presented as an agnostic barrier blocking pathogenic microbes that has localized on the mucocutaneous lining of the conjunctiva, mouth and nose, lung, or gastrointestinal tract. The cyclodextrin may bind the viral particles and/or disrupt viral entry mechanisms by removing cholesterol from viral particles to reduce infectivity. Cyclodextrins also may facilitate the removal of the viral cholesterol molecules, thus rendering them less viable.
Stan Louie; Gianluca Lazzi; Jean-Marie Bouteiller
You can read the patent on Espacenet!
